FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988598081> ?p ?o ?g. }

• W2988598081 endingPage "3942" @default.
• W2988598081 startingPage "3942" @default.
• W2988598081 abstract "In acute myeloid leukemia (AML), blasts lose their ability to differentiate into mature cells and to undergo apoptosis. Accordingly, a proapoptotic and differentiating therapy (arsenic and retinoic acid) has dramatically improved survival in acute promyelocytic leukemia; however, a similar combination therapy is not available for other AML subtypes. In 2016, inhibition of dihydroorotate dehydrogenase (DHODH), a key enzyme of the pyrimidine biosynthesis, was found to induce differentiation in several AML models; for in vivo studies, brequinar (BRQ) was utilized. Starting from BRQ and applying a scaffold-hopping replacement, we have recently developed a new DHODH inhibitor, Meds433, which could induce differentiation at a 1-log lower concentration compared to BRQ (Sainas, J Med Chem 2018). Here we characterize Meds433 with in vitro and in vivo experiments, showing that it has a significant pro-apoptotic effect in several AML cell lines, which is at least partially independent from the differentiating effect. Analyzing the kinetic of differentiation induced by Meds433 on U937 and THP1 cell lines, and comparing the data with the number of viable cells, we noticed that cells started to die before the differentiation effect could be significant. Hence, we decided to investigate the proapoptotic effect of Meds433, treating several AML (U937, THP1, OCI-AML3, NB4) and non-AML (CEM, P3j, peripheral blood mononuclear cells-PBMC) cell lines with Meds433, and analyzing the expression of Annexin V and propidium in flow cytometry. Experiments demonstrated that Meds433 had a significant pro-apoptotic effect on several AML cell lines (Fig.1), but not on non-AML cell lines. The apoptotic rate increased with the time of exposure (3 vs 6 days), allowing to obtain a good apoptotic rate also in OCI-AML3, the most resistant cell line in our hands. As for the differentiation experiments, Meds433 could induce apoptosis at a 1-log inferior concentration compared to BRQ. More interestingly, in NB4 cells, a strong apoptotic effect was not associated with any differentiating feature, indicating that DHODH inhibition can induce apoptosis directly. As NB4 is a promyelocytic cell line, we also compared the effects of ATRA (all-trans retinoic acid), Meds433 and their combination. ATRA alone was found to induce strong differentiation and mild apoptosis on NB4 cells, while Meds433 alone could induce exclusively apoptosis; finally, the combination of ATRA and Meds433 increased both the rate of differentiating and apoptotic cells compared to ATRA only. We next tried to further characterize the apoptotic effect. When experiments were performed in the presence of uridine, a downstream product of DHODH in the pyrimidine biosynthesis, the apoptotic effect was totally abrogated. This phenomenon was already observed in the differentiation experiments (Sainas, J Med Chem 2018), and it confirms that both differentiation and apoptosis are indeed caused by the pyrimidine depletion rather than off-target mechanisms. Moreover, when experiments were performed in hypoxic conditions, the rate of apoptosis did not change, suggesting that Meds433 could work in the bone marrow hypoxic niche of (leukemic) stem cells. Further analyzing the effect of Meds433 on non-AML cells, we evaluated the maturation of T-lymphocytes, from naïve to TEMRA (T effector memory RA), finding no influence at all. Finally, preliminary results from in vivo experiments show that i) Meds433 is not toxic on Balb/c mice after 5 weeks of intraperitoneal administration; ii) the half-life is limited to 4-6 hours and iii) Meds433 has a good antileukemic activity (approximately 50% reduction of the tumor volume compared with control, after an 18-day treatment of THP1-xenograft in NSG mice). In conclusion, our work demonstrates that: i) DHODH inhibition can induce apoptosis in AML cells both directly and as a result of differentiation, partially depending on the cell line; ii) Meds433 is a novel, promising antileukemic drug, with limited toxicity, which could be active on a wide variety of AML. Since continuous exposure to the drug is fundamental in the pyrimidine starvation strategy, we are currently optimizing Meds433 pharmacokinetic profile in order to maximize the in vivo antileukemic activity. Disclosures Saglio: BMS: Consultancy; Novartis: Consultancy; Ariad: Consultancy; Incyte: Consultancy; Pfizer: Consultancy; Jansen: Consultancy; Celgene: Consultancy." @default.
• W2988598081 created "2019-11-22" @default.
• W2988598081 creator A5006736025 @default.
• W2988598081 creator A5010348935 @default.
• W2988598081 creator A5012424953 @default.
• W2988598081 creator A5019949455 @default.
• W2988598081 creator A5045276884 @default.
• W2988598081 creator A5057006595 @default.
• W2988598081 creator A5059072646 @default.
• W2988598081 creator A5062037258 @default.
• W2988598081 creator A5066037224 @default.
• W2988598081 creator A5070745675 @default.
• W2988598081 creator A5072049747 @default.
• W2988598081 creator A5080055756 @default.
• W2988598081 creator A5089471144 @default.
• W2988598081 date "2019-11-13" @default.
• W2988598081 modified "2023-09-28" @default.
• W2988598081 title "Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia" @default.
• W2988598081 doi "https://doi.org/10.1182/blood-2019-128085" @default.
• W2988598081 hasPublicationYear "2019" @default.
• W2988598081 type Work @default.
• W2988598081 sameAs 2988598081 @default.
• W2988598081 citedByCount "0" @default.
• W2988598081 crossrefType "journal-article" @default.
• W2988598081 hasAuthorship W2988598081A5006736025 @default.
• W2988598081 hasAuthorship W2988598081A5010348935 @default.
• W2988598081 hasAuthorship W2988598081A5012424953 @default.
• W2988598081 hasAuthorship W2988598081A5019949455 @default.
• W2988598081 hasAuthorship W2988598081A5045276884 @default.
• W2988598081 hasAuthorship W2988598081A5057006595 @default.
• W2988598081 hasAuthorship W2988598081A5059072646 @default.
• W2988598081 hasAuthorship W2988598081A5062037258 @default.
• W2988598081 hasAuthorship W2988598081A5066037224 @default.
• W2988598081 hasAuthorship W2988598081A5070745675 @default.
• W2988598081 hasAuthorship W2988598081A5072049747 @default.
• W2988598081 hasAuthorship W2988598081A5080055756 @default.
• W2988598081 hasAuthorship W2988598081A5089471144 @default.
• W2988598081 hasBestOaLocation W29885980812 @default.
• W2988598081 hasConcept C104317684 @default.
• W2988598081 hasConcept C108634530 @default.
• W2988598081 hasConcept C148738053 @default.
• W2988598081 hasConcept C181199279 @default.
• W2988598081 hasConcept C190283241 @default.
• W2988598081 hasConcept C203014093 @default.
• W2988598081 hasConcept C2775934118 @default.
• W2988598081 hasConcept C2776601000 @default.
• W2988598081 hasConcept C2778461978 @default.
• W2988598081 hasConcept C2778729363 @default.
• W2988598081 hasConcept C2779282312 @default.
• W2988598081 hasConcept C2779865431 @default.
• W2988598081 hasConcept C2781121885 @default.
• W2988598081 hasConcept C31573885 @default.
• W2988598081 hasConcept C502942594 @default.
• W2988598081 hasConcept C54355233 @default.
• W2988598081 hasConcept C55493867 @default.
• W2988598081 hasConcept C81885089 @default.
• W2988598081 hasConcept C86803240 @default.
• W2988598081 hasConceptScore W2988598081C104317684 @default.
• W2988598081 hasConceptScore W2988598081C108634530 @default.
• W2988598081 hasConceptScore W2988598081C148738053 @default.
• W2988598081 hasConceptScore W2988598081C181199279 @default.
• W2988598081 hasConceptScore W2988598081C190283241 @default.
• W2988598081 hasConceptScore W2988598081C203014093 @default.
• W2988598081 hasConceptScore W2988598081C2775934118 @default.
• W2988598081 hasConceptScore W2988598081C2776601000 @default.
• W2988598081 hasConceptScore W2988598081C2778461978 @default.
• W2988598081 hasConceptScore W2988598081C2778729363 @default.
• W2988598081 hasConceptScore W2988598081C2779282312 @default.
• W2988598081 hasConceptScore W2988598081C2779865431 @default.
• W2988598081 hasConceptScore W2988598081C2781121885 @default.
• W2988598081 hasConceptScore W2988598081C31573885 @default.
• W2988598081 hasConceptScore W2988598081C502942594 @default.
• W2988598081 hasConceptScore W2988598081C54355233 @default.
• W2988598081 hasConceptScore W2988598081C55493867 @default.
• W2988598081 hasConceptScore W2988598081C81885089 @default.
• W2988598081 hasConceptScore W2988598081C86803240 @default.
• W2988598081 hasIssue "Supplement_1" @default.
• W2988598081 hasLocation W29885980811 @default.
• W2988598081 hasLocation W29885980812 @default.
• W2988598081 hasOpenAccess W2988598081 @default.
• W2988598081 hasPrimaryLocation W29885980811 @default.
• W2988598081 hasRelatedWork W129504940 @default.
• W2988598081 hasRelatedWork W1973107024 @default.
• W2988598081 hasRelatedWork W2002758987 @default.
• W2988598081 hasRelatedWork W2038157705 @default.
• W2988598081 hasRelatedWork W2060560241 @default.
• W2988598081 hasRelatedWork W2065514457 @default.
• W2988598081 hasRelatedWork W2125898596 @default.
• W2988598081 hasRelatedWork W2338418129 @default.
• W2988598081 hasRelatedWork W2588809829 @default.
• W2988598081 hasRelatedWork W2988852042 @default.
• W2988598081 hasVolume "134" @default.
• W2988598081 isParatext "false" @default.
• W2988598081 isRetracted "false" @default.
• W2988598081 magId "2988598081" @default.
• W2988598081 workType "article" @default.